Abstract
Denosumab has been proven to be at least as effective with respect to zoledronic acid in preventing skeletal-related events in patients with bone metastases from solid tumors. Although denosumab can be considered to have a more favorable toxicity profile compared to zoledronic acid in terms of kidney toxicity and flu-like symptoms, hypocalcemia is twice as frequent with denosumab. Importantly, denosumab is not metabolized by the kidney and it may be employed even in patients with severe kidney failure. Like zoledronic acid, denosumab is administered with oral calcium and vitamin D. As conversion of vitamin D to its active form is progressively impaired with a creatinine clearance <70 ml/min, we speculate that calcitriol may be a better option than vitamin D in denosumab-treated patients with impaired kidney function.
| Original language | English |
|---|---|
| Pages (from-to) | 149-151 |
| Number of pages | 3 |
| Journal | Expert Opinion on Biological Therapy |
| Volume | 13 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2013 |
Fingerprint
Keywords
- bone metastasis
- calcitriol
- denosumab
- zoledronic acid
ASJC Scopus subject areas
- Pharmacology
- Clinical Biochemistry
- Drug Discovery
Cite this
Calcitriol : A better option than vitamin D in denosumab-treated patients with kidney failure? / Buonerba, Carlo; Caraglia, Michele; Malgieri, Simona; Perri, Francesco; Bosso, Davide; Federico, Piera; Ferro, Matteo; Rizzo, Mimma; Palmieri, Giovannella; Di Lorenzo, Giuseppe.
In: Expert Opinion on Biological Therapy, Vol. 13, No. 2, 02.2013, p. 149-151.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Calcitriol
T2 - A better option than vitamin D in denosumab-treated patients with kidney failure?
AU - Buonerba, Carlo
AU - Caraglia, Michele
AU - Malgieri, Simona
AU - Perri, Francesco
AU - Bosso, Davide
AU - Federico, Piera
AU - Ferro, Matteo
AU - Rizzo, Mimma
AU - Palmieri, Giovannella
AU - Di Lorenzo, Giuseppe
PY - 2013/2
Y1 - 2013/2
N2 - Denosumab has been proven to be at least as effective with respect to zoledronic acid in preventing skeletal-related events in patients with bone metastases from solid tumors. Although denosumab can be considered to have a more favorable toxicity profile compared to zoledronic acid in terms of kidney toxicity and flu-like symptoms, hypocalcemia is twice as frequent with denosumab. Importantly, denosumab is not metabolized by the kidney and it may be employed even in patients with severe kidney failure. Like zoledronic acid, denosumab is administered with oral calcium and vitamin D. As conversion of vitamin D to its active form is progressively impaired with a creatinine clearance <70 ml/min, we speculate that calcitriol may be a better option than vitamin D in denosumab-treated patients with impaired kidney function.
AB - Denosumab has been proven to be at least as effective with respect to zoledronic acid in preventing skeletal-related events in patients with bone metastases from solid tumors. Although denosumab can be considered to have a more favorable toxicity profile compared to zoledronic acid in terms of kidney toxicity and flu-like symptoms, hypocalcemia is twice as frequent with denosumab. Importantly, denosumab is not metabolized by the kidney and it may be employed even in patients with severe kidney failure. Like zoledronic acid, denosumab is administered with oral calcium and vitamin D. As conversion of vitamin D to its active form is progressively impaired with a creatinine clearance <70 ml/min, we speculate that calcitriol may be a better option than vitamin D in denosumab-treated patients with impaired kidney function.
KW - bone metastasis
KW - calcitriol
KW - denosumab
KW - zoledronic acid
UR - http://www.scopus.com/inward/record.url?scp=84872186108&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872186108&partnerID=8YFLogxK
U2 - 10.1517/14712598.2012.756470
DO - 10.1517/14712598.2012.756470
M3 - Article
VL - 13
SP - 149
EP - 151
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
SN - 1471-2598
IS - 2
ER -